These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6582796)

  • 1. [Immediate cardiac toxicity of rubidazone. A case reversible by isoproterenol].
    Larmignat P; Casassus P; Pourriat JL; Leroux G; Chaux F; Cupa M
    Ann Med Interne (Paris); 1983; 134(7):647-50. PubMed ID: 6582796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
    Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
    Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies.
    Jacquillat C; Weil M; Gemon-Auclerc MF; Izrael V; Bussel A; Boiron M; Bernard J
    Cancer; 1976 Feb; 37(2):653-9. PubMed ID: 1062226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)].
    Bauters F; Jouet JP; Huart JJ; Jude B; Toussaint B; Goudemand M
    Lille Med; 1980 Dec; 25(10):559-68. PubMed ID: 6936592
    [No Abstract]   [Full Text] [Related]  

  • 8. Daunorubicin-induced hyperpigmentation.
    Pol RR; Wright A; Hill A
    Br J Haematol; 2010 Dec; 151(5):414. PubMed ID: 21029070
    [No Abstract]   [Full Text] [Related]  

  • 9. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiogenic shock caused by 5-fluorouracil].
    Mazet C; Dellinger A; Vital Durand D; Adnaoui M; Fournier G; Levrat R
    Ann Cardiol Angeiol (Paris); 1990 Mar; 39(3):179-80. PubMed ID: 2344152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
    Okamoto M; Miyazaki H; Tsuzuki M; Ino T; Ezaki K; Hirano M
    Rinsho Ketsueki; 1995 Nov; 36(11):1305-10. PubMed ID: 8691573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rubidazone in the treatment of recurrent acute leukemia in children. A Pediatric Oncology Group Study.
    Ragab AH; Boyett JM; Frankel L; Falletta J
    Cancer; 1986 Apr; 57(8):1461-3. PubMed ID: 3948126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
    Lemez P; Maresová J
    Neoplasma; 1996; 43(6):417-9. PubMed ID: 8996568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Lemez P; Maresová J
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model systems for cardiotoxic effects of anthracyclines.
    Zbinden G; Bachmann E; Holderegger C
    Antibiot Chemother (1971); 1978; 23():255-70. PubMed ID: 348084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac toxicity in cancer therapy].
    Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
    Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
    Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
    Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
    Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.